Health AI Central
Share:
Peer-Reviewed Publication
Adv Ther2024;41(6):2367-2380.June 1, 2024Journal Article

The Use of Precision Epigenetic Methods for the Diagnosis and Care of Stable Coronary Heart Disease Reduces Healthcare Costs.

David Frisvold1, Meeshanthini Dogan2, Timur Dogan2, Khullani Abdullahi2, Tyler Koep2, Robert Philibert3,4
1Department of Economics, University of Iowa, Iowa City, IA, 52242, USA.
2Cardio Diagnostics Inc, Chicago, IL, 60654, USA.
3Cardio Diagnostics Inc, Chicago, IL, 60654, USA. rphilibert@cardiodiagnosticsinc.com.
4Department of Psychiatry, University of Iowa, Iowa City, IA, 52242, USA. rphilibert@cardiodiagnosticsinc.com.
PubMed PMC DOI PDF

Abstract

INTRODUCTION: The cost of secondary prevention of coronary heart disease (CHD) is continuing to increase, with a substantial portion of this acceleration being driven by the expense of confirmatory diagnostic testing. Conceivably, newly developed precision epigenetic technologies could drive down these costs. However, at the current time, their impact on overall expense for CHD care is poorly unde…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.